Genetics and Epigenetics of Parathyroid Carcinoma.
DNA methylation
epigenetic changes
gene mutation
long non-coding RNAs
microRNAs
molecular signatures
parathyroid carcinoma
tumor suppressor genes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2021
accepted:
28
01
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
26
4
2022
Statut:
epublish
Résumé
Parathyroid carcinoma (PC) is an extremely rare malignancy, accounting less than 1% of all parathyroid neoplasms, and an uncommon cause of primary hyperparathyroidism (PHPT), characterized by an excessive secretion of parathyroid hormone (PTH) and severe hypercalcemia. As opposed to parathyroid hyperplasia and adenomas, PC is associated with a poor prognosis, due to a commonly unmanageable hypercalcemia, which accounts for death in the majority of cases, and an overall survival rate of 78-85% and 49-70% at 5 and 10 years after diagnosis, respectively. No definitively effective therapies for PC are currently available. The mainly employed treatment for PC is the surgical removal of tumoral gland(s). Post-surgical persistent or recurrent disease manifest in about 50% of patients. The comprehension of genetic and epigenetic bases and molecular pathways that characterize parathyroid carcinogenesis is important to distinguish malignant PCs from benign adenomas, and to identify specific targets for novel therapies. Germline heterozygote inactivating mutations of the
Identifiants
pubmed: 35282432
doi: 10.3389/fendo.2022.834362
pmc: PMC8908968
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
834362Informations de copyright
Copyright © 2022 Marini, Giusti, Palmini, Perigli, Santoro and Brandi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocr Relat Cancer. 2010 May 18;17(2):513-24
pubmed: 20304979
J Clin Endocrinol Metab. 2012 Sep;97(9):E1774-81
pubmed: 22740705
J Mol Cell Biol. 2018 Aug 1;10(4):302-315
pubmed: 30053090
Mol Carcinog. 2016 Sep;55(9):1329-42
pubmed: 26293643
Cancers (Basel). 2021 Aug 05;13(16):
pubmed: 34439105
Cancer Lett. 2013 Feb 28;329(2):164-73
pubmed: 23142219
J Clin Invest. 1989 Jun;83(6):2034-40
pubmed: 2723071
Mol Cell Biol. 2005 Jun;25(12):5052-60
pubmed: 15923622
J Biol Chem. 2003 Sep 5;278(36):33625-8
pubmed: 12876293
Noncoding RNA Res. 2018 May 22;3(3):131-143
pubmed: 30175286
J Clin Endocrinol Metab. 2012 Jul;97(7):E1307-15
pubmed: 22544915
Mol Cell Biol. 2005 Jan;25(2):612-20
pubmed: 15632063
JCO Oncol Pract. 2021 Jan;17(1):17-21
pubmed: 32040373
Mol Cell. 2011 Sep 16;43(6):904-14
pubmed: 21925379
Nucleic Acids Res. 2010 Jan;38(2):382-90
pubmed: 19906718
Mol Cancer Ther. 2016 May;15(5):1082-94
pubmed: 26908628
Ann Otol Rhinol Laryngol. 2007 Dec;116(12):928-33
pubmed: 18217513
J Cell Biochem. 2018 Jan;119(1):691-700
pubmed: 28636190
J Mol Endocrinol. 2012 Jul 26;49(2):115-24
pubmed: 22767050
J Clin Endocrinol Metab. 2022 Jan 18;107(2):e783-e792
pubmed: 34453169
Am J Surg Pathol. 2019 Jan;43(1):35-46
pubmed: 29324469
Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):781-796
pubmed: 34697069
Surgery. 2003 Dec;134(6):932-9; discussion 939-40
pubmed: 14668725
Mol Endocrinol. 2005 Oct;19(10):2603-9
pubmed: 15928311
Mol Cell. 2016 Nov 17;64(4):673-687
pubmed: 27840030
Cell. 2006 Apr 21;125(2):327-41
pubmed: 16630820
Mol Cancer. 2010 Nov 15;9:294
pubmed: 21078161
Endocr Relat Cancer. 2010 Feb 18;17(1):135-46
pubmed: 19926710
Antioxidants (Basel). 2017 Nov 03;6(4):
pubmed: 29099803
Front Horm Res. 2013;41:149-65
pubmed: 23652676
Endocrine. 2016 Oct;54(1):55-59
pubmed: 26876532
RNA. 2012 Jan;18(1):135-44
pubmed: 22114321
Ann Surg Oncol. 2011 Apr;18(4):1158-65
pubmed: 21086055
RNA Biol. 2019 Sep;16(9):1228-1236
pubmed: 31213128
Mol Cancer. 2016 May 27;15(1):43
pubmed: 27233618
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1567-1572
pubmed: 29128359
Lab Invest. 2017 Dec;97(12):1488-1499
pubmed: 28920943
Mol Cancer Res. 2007 Feb;5(2):183-93
pubmed: 17314275
Autophagy. 2015;11(12):2213-32
pubmed: 26553592
Hum Mutat. 2017 Dec;38(12):1621-1648
pubmed: 28881068
Endocr Relat Cancer. 2019 Jul;26(7):R441-R464
pubmed: 31085770
Genet Res Int. 2011;2011:275802
pubmed: 22567348
Endocr Relat Cancer. 2019 Feb;26(2):163-176
pubmed: 30403657
J Bone Miner Metab. 2014 Jul;32(4):351-66
pubmed: 24442824
Int J Clin Exp Pathol. 2015 Oct 01;8(10):12500-8
pubmed: 26722437
Clin Cancer Res. 2004 Oct 1;10(19):6629-37
pubmed: 15475453
Epigenetics. 2013 Jun;8(6):646-55
pubmed: 23764768
PLoS One. 2010 Mar 01;5(3):e9472
pubmed: 20208994
Oncotarget. 2015 Jun 30;6(18):16287-303
pubmed: 25915537
Sci Rep. 2015 Nov 19;5:16714
pubmed: 26581166
J Bone Miner Res. 2020 Dec;35(12):2423-2431
pubmed: 32780442
J Clin Endocrinol Metab. 2015 Feb;100(2):E360-4
pubmed: 25387265
Endocr Relat Cancer. 2014 Feb 27;21(2):231-9
pubmed: 24292603
JCI Insight. 2017 Mar 23;2(6):e92061
pubmed: 28352668
Cancer Res. 2003 Jan 15;63(2):424-31
pubmed: 12543798
J Pathol. 2013 Jul;230(3):249-60
pubmed: 23616356
Genes Chromosomes Cancer. 2011 Sep;50(9):735-45
pubmed: 21638518
Endocr Relat Cancer. 2021 Feb;28(2):111-134
pubmed: 33290252
J Mol Endocrinol. 2017 Feb;58(2):91-103
pubmed: 27872158
Endocrinology. 2018 Aug 1;159(8):3061-3068
pubmed: 29982334
Int J Mol Sci. 2021 Feb 18;22(4):
pubmed: 33670622
Oncol Lett. 2017 Dec;14(6):7276-7282
pubmed: 29344163
Endocr Relat Cancer. 2018 Feb;25(2):R59-R82
pubmed: 29146581
Eur J Endocrinol. 2021 Oct 25;185(6):803-812
pubmed: 34606470
Nat Rev Endocrinol. 2015 Mar;11(3):151-60
pubmed: 25560704
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33079727
J Clin Invest. 2001 May;107(9):1093-102
pubmed: 11342573
Cancer Res. 2004 Oct 15;64(20):7405-11
pubmed: 15492263
Clin Transl Oncol. 2021 Mar;23(3):514-525
pubmed: 32656583